Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 February 2026, providing investors with the latest insights into its performance and outlook.

Bliss GVS Pharma Ltd demonstrated robust intraday performance on 29 Jan 2026, surging to an intraday high of Rs 178.65, marking a 7.54% increase from the previous close. The stock outperformed its sector and broader market indices, continuing its upward momentum amid positive trading activity.

Bliss GVS Pharma Ltd demonstrated robust intraday performance on 23 Jan 2026, surging to an intraday high of Rs 168, marking an 8.46% increase from previous levels. The stock outperformed its sector and broader market indices, reflecting strong trading momentum throughout the session.

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. While the rating change occurred then, the analysis and financial metrics discussed here reflect the company’s current position as of 22 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Bliss GVS Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from bullish to mildly bullish territory. Despite a recent decline in share price, the stock’s technical profile presents a complex picture, reflecting both resilience and caution for investors navigating the Pharmaceuticals & Biotechnology sector.

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Bliss GVS Pharma Ltd emerged as one of the most actively traded stocks by value on 7 January 2026, reflecting strong investor interest and institutional participation. The pharmaceutical company’s shares surged to a new 52-week high, supported by a recent upgrade in its MarketsMOJO Mojo Grade from Sell to Hold, signalling improving fundamentals and market sentiment.

Bliss GVS Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable surge in trading volume on 7 January 2026, accompanied by robust price appreciation and positive technical signals. The stock outperformed its sector and broader market indices, signalling renewed investor interest and potential accumulation.

Bliss GVS Pharma Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone today by hitting a new 52-week high of Rs.195.85. This achievement underscores the stock’s robust momentum amid a mixed market backdrop, reflecting strong buying interest and sustained upward movement over recent sessions.

Bliss GVS Pharma Ltd has surged to a fresh 52-week high of Rs.190.95, marking a significant milestone in its stock performance. This new peak reflects robust momentum driven by strong intraday gains and sustained buying interest, outpacing its sector and broader market indices.

Bliss GVS Pharma Ltd (BLISSGVS) emerged as one of the most actively traded stocks on 6 Jan 2026, registering a remarkable volume surge of over 2.66 crore shares and a significant price gain of 10.62% on the day. The stock outperformed its Pharmaceuticals & Biotechnology sector peers and the broader market, signalling renewed investor interest and potential accumulation in this small-cap pharmaceutical player.

Bliss GVS Pharma Ltd demonstrated robust intraday performance on 6 Jan 2026, surging to an intraday high of Rs 177.75, marking an 8.38% gain for the day and significantly outperforming its Pharmaceuticals & Biotechnology sector peers.

Bliss GVS Pharma Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early January 2026. Despite a recent downgrade in its market rating from Sell to Hold, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the evolving technical landscape of Bliss GVS Pharma, contextualising its price action against broader market trends and sectoral performance.

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the company’s current position as of 31 December 2025, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Bliss GVS Pharma has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial and technical developments. The pharmaceutical company’s assessment metrics have been adjusted following a period of notable stock price movement and evolving fundamental indicators.